ERX - A thread for everyone

Taken from the Reuters link:



MGI's second immunotherapy compound in clinical development is ZYC300. ZYC300, an encapsulated plasmid encoding a commonly expressed tumor antigen, has completed a phase I/IIa trial in 17 patients with late-stage metastatic hematological and solid tumors. The enzyme cytochrome P450 1B1 (CYP1B1), is encoded by the ZYC300 plasmid.

Taken from the MGI web site:




ZYC300 is specifically designed to activate a response that kills cells expressing a newly discovered target, CYP1B1, a protein with high expression in many types of cancer, but restricted expression in normal tissue. In vitro experiments demonstrated that CYP1B1 specific human T cells kill CYP1B1 expressing tumor cells taken directly from patients. Additional data indicates that injection of ZYC300 activates cells that kill tumor cells. A phase 1/2a trial of ZYC300 in late-stage metastatic cancer patients has been completed. A phase 1/2b trial will begin in 2006.

If you check the Reuters link you will find that it is not news but is just part of a company summary, which if you connect to it now you find perhaps unsurprisingly that it will give you a date of December 23rd ie today. Cherck again and you will see that the last news release posted by Reuters is in fact dated December 14th.

Now some of you maybe posting this as news in error whereas others of you know full well that you are deliberately trying to present old news as something new. To the offenders and you know who you are, I suggest that it is time for you to grow up – perhaps this could be your new years resolution.